Main content

    Liver Cancer
    (Hepatoma / Hepatocellular Carcinoma / HCC)

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    First Line Treatment  |  Second Line Treatment

    First Line Treatment

    Title: An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
    Description: This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC)
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, who have a Histological or cytological diagnosis of HCC
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Eisai E7080J081-116

    Back to top

    Second Line Treatment

    Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Therapy With Sorafenib
    Description: The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, with a diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Lilly JVDE

    Title: Phase 1 Study of ADI PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
    Description: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
    Investigator: Ari Baron, MD
    Eligibility: Patients with HCC who failed sorafenib, with documented PD or AEs that resulted in discontinuance of that agent.
    Status: Open
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Polaris 2013-001

    Title: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
    Description: This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer.
    Investigator: Ari Baron, MD
    Eligibility: Patients with HCC who failed sorafenib, with documented PD or AEs that resulted in discontinuance of that agent.
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study RTOG 1112

    • updated 07/2018

    Back to top